MaxCyte [MXCT] vs Abbott Laboratories [ABT] Detailed Stock Comparison

MaxCyte Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: MaxCyte Inc. wins in 5 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric MaxCyte Inc. Abbott Laboratories Better
P/E Ratio (TTM) -2.07 25.97 Abbott Laboratories
Price-to-Book Ratio 0.55 3.09 MaxCyte Inc.
Debt-to-Equity Ratio 10.46 26.79 MaxCyte Inc.
PEG Ratio 0.21 -1.41 MaxCyte Inc.
EV/EBITDA -0.20 13.74 Abbott Laboratories
Profit Margin (TTM) -135.14% 13.90% Abbott Laboratories
Operating Margin (TTM) -94.81% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -23.63% 12.36% Abbott Laboratories
Return on Assets (TTM) -12.60% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-36.18M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -49.09% -34.98% Abbott Laboratories
Price-to-Sales Ratio (TTM) 2.88 3.57 MaxCyte Inc.
Enterprise Value $7.89M $166.96B Abbott Laboratories
EV/Revenue Ratio 0.24 3.70 MaxCyte Inc.
Gross Profit Margin (TTM) 77.95% N/A N/A
Revenue per Share (TTM) $0 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.42 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.45 0.78 Abbott Laboratories
Short % of Float 5.23% 1.53% Abbott Laboratories

MaxCyte Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

MXCT
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
MaxCyte Inc.3.57%0.87%11.54%43.21%-22.15%-25.16%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
MaxCyte Inc.-49.09%-77.10%-93.41%-93.41%-93.41%-93.41%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: MaxCyte Inc. vs Abbott Laboratories

MetricMXCTABT
Market Information
Market Cap i$92.07M$160.70B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i734,69613,495,583
90 Day Avg. Volume i895,75912,934,461
Last Close$1.16$88.67
52 Week Range$0.64 - $2.37$81.97 - $139.06
% from 52W High-51.05%-36.24%
All-Time High$17.44 (Jul 26, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-93.35%-37.82%
Growth Metrics
Quarterly Revenue Growth-0.16%0.08%
Quarterly Earnings Growth-0.16%-0.19%
Financial Health
Profit Margin (TTM) i-1.35%0.14%
Operating Margin (TTM) i-0.95%0.17%
Return on Equity (TTM) i-0.24%0.12%
Debt to Equity (MRQ) i10.4626.79
Cash & Liquidity
Book Value per Share (MRQ)$1.61$30.02
Cash per Share (MRQ)$0.96$5.14
Operating Cash Flow (TTM) i$-34,410,000$10.80B
Levered Free Cash Flow (TTM) i$-15,469,750$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: MaxCyte Inc. vs Abbott Laboratories

MetricMXCT (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-2.0725.97
Forward P/E i-3.3315.29
PEG Ratio i0.21-1.41
Price to Sales (TTM) i2.883.57
Price to Book (MRQ) i0.553.09
Market Capitalization
Market Capitalization i$92.07M$160.70B
Enterprise Value i$7.89M$166.96B
Enterprise Value Metrics
Enterprise to Revenue i0.243.70
Enterprise to EBITDA i-0.2013.74
Risk & Other Metrics
Beta i1.450.78
Book Value per Share (MRQ) i$1.61$30.02

Financial Statements Comparison: MaxCyte Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMXCT (2025)ABT (2025)
Revenue/Sales i33.03M44.33B
Cost of Goods Sold i6.22M19.32B
COGS % of Revenue i18.8%43.6%
Gross Profit i26.80M25.01B
Gross Margin i81.2%56.4%
Research & Development i20.82M2.94B
Operating Income (EBIT) i-45.29M8.05B
Operating Margin i-137.1%18.2%
EBITDA i-33.53M12.03B
EBITDA Margin i-101.5%27.1%
Pre-Tax Income i-44.63M8.47B
Pre-Tax Income % of Revenue i-135.1%19.1%
Income Tax i01.94B
Income Tax % of Revenue i0.0%4.4%
Net Income (Profit) i-44.63M6.52B
Profit Margin i-135.1%14.7%

Balance Sheet & Liquidity Metrics

MetricMXCT (2025)ABT (2025)
Cash & Equivalents i20.07M8.52B
Total Current Assets i118.37M26.00B
Total Current Assets % of Revenue i358.4%58.6%
Total Current Liabilities i14.27M16.50B
Total Current Liabilities % of Revenue i43.2%37.2%
Long-Term Debt i16.49M10.83B
Long-Term Debt % of Revenue i49.9%24.4%
Total Shareholders Equity i171.49M52.77B
Retained Earnings i-261.48M49.78B
Retained Earnings % of Revenue i-791.7%112.3%
Property, Plant & Equipment i12.84M17.57B

Cash Flow Statement Comparison

MetricMXCT (2025)ABT (2025)
Operating Cash Flow i-35.79M10.80B
Operating Cash Flow % of Revenue i-108.4%24.4%
Capital Expenditures i-1.77M-2.17B
Free Cash Flow i-36.18M7.40B
FCF Margin i-109.5%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricMXCTABT
Shares Short i5.55M23.83M
Short Ratio i5.361.93
Short % of Float i5.23%1.53%
Shares Outstanding i106.79M1.74B
Float Shares i105.71M1.73B
% Held by Insiders i1.40%0.54%
% Held by Institutions i65.81%82.23%
% Held by Public i32.79%17.23%

Dividend Analysis & Yield Comparison: MaxCyte Inc. vs Abbott Laboratories

MetricMXCTABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026